NASDAQ · PCRX
Healthcare · Drug Manufacturers - Specialty & Generic
$24.08
Up+$0.83 (+3.45%)
Updated Sep 16, 2026, 11:28 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PCRX closed at $24.08 after 20 trading sessions, up 0.33% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $24.63 | $24.94 | $23.65 | $24.08 | 824.51K |
| Sep 14, 2026 | $25.71 | $25.99 | $24.65 | $24.68 | 418.44K |
| Sep 11, 2026 | $25.43 | $25.57 | $25.18 | $25.36 | 538.04K |
| Sep 10, 2026 | $25.92 | $25.995 | $25.10 | $25.16 | 733.77K |
| Sep 9, 2026 | $25.62 | $25.88 | $25.13 | $25.88 | 571.74K |
| Sep 8, 2026 | $25.98 | $26.41 | $25.675 | $25.87 | 386.42K |
| Sep 4, 2026 | $26.38 | $26.65 | $26.31 | $26.35 | 481.69K |
| Sep 3, 2026 | $26.74 | $26.84 | $26.32 | $26.60 | 598.52K |
| Sep 2, 2026 | $26.52 | $26.91 | $26.24 | $26.58 | 610.79K |
| Sep 1, 2026 | $26.01 | $26.50 | $25.975 | $26.47 | 729.46K |
| Aug 31, 2026 | $25.75 | $26.07 | $25.455 | $25.90 | 380.51K |
| Aug 28, 2026 | $25.74 | $26.045 | $25.555 | $25.76 | 483.55K |
| Aug 27, 2026 | $25.63 | $26.031 | $25.36 | $25.83 | 413.4K |
| Aug 26, 2026 | $25.46 | $26.025 | $25.315 | $25.90 | 506.09K |
| Aug 25, 2026 | $24.89 | $25.585 | $24.795 | $25.53 | 379.71K |
| Aug 24, 2026 | $24.60 | $25.04 | $24.49 | $24.86 | 336.67K |
| Aug 21, 2026 | $23.91 | $24.72 | $23.66 | $24.67 | 475.87K |
| Aug 20, 2026 | $24.11 | $24.405 | $23.72 | $23.83 | 402.8K |
| Aug 19, 2026 | $24.04 | $24.58 | $24.04 | $24.36 | 336.18K |
| Aug 18, 2026 | $23.32 | $24.045 | $23.32 | $24.00 | 443.57K |
The latest Smart Investors Daily articles mentioning PCRX.
PCRX research
Company profile and research snapshot.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | Market Perform | — |
| Aug 5, 2026 | Needham | Buy | — |
| Aug 5, 2026 | RBC Capital | Sector Perform | — |
| Jul 1, 2026 | HC Wainwright & Co. | Buy | — |
| May 1, 2026 | RBC Capital | Sector Perform | — |
No generated briefing is available yet.
ChartMill · Sep 11, 2026
Pacira Biosciences (PCRX) trades deeply below earnings and cash flow peers, backed by solid finances but slow growth in non-opioid pain care.
Yahoo · Sep 9, 2026
BRISBANE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on September 2, 2026 to five new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing R
Benzinga · Sep 9, 2026
Leerink Partners analyst Daniel Clark initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Market Perform rating and announces Price Target of $28.
Yahoo · Sep 4, 2026
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PCRX.
